Skip to main content
SpringerLink
Log in

Evaluation of tumor markers CA-125 and CEA in acute myocardial infarction

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Serum carbohydrate antigen (CA-125) and carcinoembryonic antigen (CEA) have always been of clinical importance in the diagnosis and follow-up of various tumors. This study was devised to investigate the relationship between these tumor markers and acute myocardial infarction (MI). Seventy consecutive cases (59 male patients with a diagnosis of acute ST segment elevation MI and 11 male patients with a diagnosis of non-ST segment elevation MI; mean age, 57±8.2 y) were admitted to the University Medical Center and were included in this study as “the patient group.” All patients in the patient group underwent transthoracic echocardiographic examination on the third day of hospitalization. On the basis of echocardiographic findings, these 70 patients were grouped according to left ventricular ejection fraction (EF) values; EF < 55% (group 1) (n=40) and EF≥55% (group 2) (n=30). Other parameters, including systolic pulmonary artery pressure (sPAP) and mean pulmonary artery pressure (mPAP), were also measured on transthoracic echocardiography. Serial blood samples (for follow-up of myocardial enzymes (eg, creatine kinase MB [CKMB], troponin I [TnI], troponin T, and other routine parameters) were drawn from each patient. Serum concentrations of CEA and CA-125 measured at the 72nd hour of hospitalization and peak serum concentrations of CKMB and TnI in the patient group were collected for comparison between subgroups (groups 1 and 2) and with “the control group”, which included 30 subjects (mean age, 54±7.6 y) with no history or evidence of overt cardiac disease and with normal echocardiographic findings. The presence of any condition characterized by potential elevations in CA-125, CEA, and myocardial enzymes (CKMB, TnI) was considered an exclusion criterion. Patients included in patient groups 1 and 2 differed significantly in terms of mean EF, mean sPAP, mean mPAP, and mean CA-125 values (P < .001 for CA-125;P < .05 for the other values). EF was found to be negatively correlated with sPAP (r=-0.692,P=.000) and mPAP (r=-0.393,P=.001). EF was also negatively correlated with CA-125 (r=-0.557,P=.000). A positive correlation was noted between CA-125 and sPAP (r=0.396,P=.001) and between CA-125 and mPAP (r=0.754,P=.000). A statistically significant difference was identified between the patient and control groups with regard to values for EF, PAP, CA-125, and myocardial enzymes (CKMB and TnI) (P < .05 for mPAP;P < .001 for the other values). The serum concentration of CA-125, but not of CEA, may be elevated in those with acute MI compared with normal subjects. Regardless of the presence of pulmonary hypertension, elevations in CA-125 during myocardial infarction were significantly correlated with the severity of left ventricular systolic dysfunction on transthoracic echocardiography.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.N Engl J Med. 1983; 309: 883–887.

    Article  PubMed  Google Scholar 

  2. Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumor marker.Br J Cancer. 1984; 50: 765–769.

    PubMed  CAS  Google Scholar 

  3. Lazzarino M, Orlandi E, Klersy C, et al. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin’s lymphoma: correlation with tumor parameters and disease activity.Cancer. 1998; 82: 576–582.

    Article  PubMed  CAS  Google Scholar 

  4. Sakamoto K, Haga Y, Yoshimura R, Egami H, Yokoyama Y, Akagi M. Comparative effectiveness of the tumour diagnostics CA 19–9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system.Gut. 1987; 28: 323–329.

    Article  PubMed  CAS  Google Scholar 

  5. Klapdor R, Klapdor U, Bahlo M, et al. CA 125 in carcinomas of the digestive tract.Dtsch Med Wochenschr. 1984; 199: 1949–1954.

    Article  Google Scholar 

  6. Bergmann JF, Bidart JM, George M, Beaugrand M, Levy VG, Bohuon C. Elevation of CA 125 in patients with benign and malignant ascites.Cancer. 1987; 59: 213–217.

    Article  PubMed  CAS  Google Scholar 

  7. Seo T, Ikeda Y, Onaka H, et al. Usefulness of serum CA125 measurement for monitoring pericardial effusion.Jpn Circ J. 1993; 57: 489–494.

    PubMed  CAS  Google Scholar 

  8. Nagele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rodiger W. CA125 and its relation to cardiac function.Am Heart J. 1999; 137: 1044–1049.

    Article  PubMed  CAS  Google Scholar 

  9. D’Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities and short term prognosis.J Am Coll Cardiol. 2003; 41: 1805–1811.

    Article  PubMed  CAS  Google Scholar 

  10. Fletcher RH. Carcinoembryonic antigen.Ann Intern Med. 1996; 104: 66–73.

    Google Scholar 

  11. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer.J Clin Oncol. 1996; 14: 2843–2877.

    Google Scholar 

  12. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of left ventricle by two-dimensional echocardiography. American Society of Echocardiography on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.J Am Soc Echocardiogr. 1989; 2: 358–367.

    PubMed  CAS  Google Scholar 

  13. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer.Cancer Treat Rev. 1995; 21: 215–245.

    Article  PubMed  CAS  Google Scholar 

  14. Ozguroglu M, Turna H, Demir G, et al. Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin’s lymphoma.Am J Clin Oncol. 1999; 22: 615–618.

    Article  PubMed  CAS  Google Scholar 

  15. Lazzarino M, Orlandi E, Klersy C, et al. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin’s lymphoma: correlation with tumor parameters and disease activity.Cancer. 1998; 82: 576–582.

    Article  PubMed  CAS  Google Scholar 

  16. Zacharos ID, Efstathiou SD, Petreli E, et al. The prognostic significance of CA 125 in patients with non-Hodgkin’s lymphoma.Eur J Haematol. 2002; 69: 221–226.

    Article  PubMed  CAS  Google Scholar 

  17. Gallup DG, Talledo E. Management of the adnexal mass in the 1990s.South Med J. 1997; 90: 972–981.

    Article  PubMed  CAS  Google Scholar 

  18. Halila H, Stenman UH, Seppala M. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy.Cancer. 1986; 57: 1327–1329.

    Article  PubMed  CAS  Google Scholar 

  19. Barbieri RL, Niloff JM, Bast RC, Schaetzi RN, Kirstner RW, Knapp RC. Elevated serum concentrations of CA 125 in patients with advanced endometriosis.Fertil Steril. 1986; 45: 630–634.

    PubMed  CAS  Google Scholar 

  20. Candocia SA, Locker GY. Elevated serum CA 125 secondary to tuberculous peritonitis.Cancer. 1993; 72: 2016–2018.

    Article  PubMed  CAS  Google Scholar 

  21. Okazaki K, Mizuno K, Katoh K, Hashomoto S, Fukuchi S. Tuberculous peritonitis with extraordinarily high serum CA 125.J Med. 1992; 23: 353–361.

    PubMed  CAS  Google Scholar 

  22. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer.Cancer Treat Rev. 1995; 21: 215–245.

    Article  PubMed  CAS  Google Scholar 

  23. Gallup DG, Talledo E. Management of the adnexal mass in the 1990s.South Med J. 1997; 90: 972–981.

    Article  PubMed  CAS  Google Scholar 

  24. Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.Obstet Gynecol. 1988; 72: 23–27.

    PubMed  CAS  Google Scholar 

  25. Kouris NT, Zacharos ID, Kontogianni DD, et al. The significance of CA 125 levels in patients with chronic congestive heart failure: correlation with clinical and echocardiographic parameters.Eur J Heart Fail. 2005; 7: 199–203.

    Article  PubMed  CAS  Google Scholar 

  26. Camera A, Villa MR, Rocco S, et al. Increased CA 125 serum levels in patients with advanced acute leukemia with serosal involvement.Cancer. 2000; 88: 75–78.

    Article  PubMed  CAS  Google Scholar 

  27. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S. Circulating interleukin-6 in severe heart failure.Am J Cardiol. 1997; 79: 1128–1131.

    Article  PubMed  CAS  Google Scholar 

  28. Kubonishi I, Bandobashi K, Murata N, et al. High serum levels of CA125 and interleukin-6 in a patient with Ki-1 lymphoma.Br J Haematol. 1997; 98: 450–452.

    Article  PubMed  CAS  Google Scholar 

  29. Maytin M, Colucci WS. Molecular and cellular mechanisms of myocardial remodeling.J Nucl Cardiol. 2002; 9: 319–327.

    Article  PubMed  Google Scholar 

  30. Thaik CM, Calderone A, Takahashi N, Colucci WS. Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes.J Clin Invest. 1995; 96: 1093–1099.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Cumhuriyet University, 58100, Sivas, Turkey

    Kenan Yalta MD, Ahmet Yilmaz MD, Okan Onur Turgut MD, Mehmet Birhan Yilmaz MD, Filiz Karadas MD, Can Yontar MD & Izzet Tandogan MD

  2. Department of Nuclear Medicine, Cumhuriyet University, Turkey

    Taner Erselcan MD

Authors
  1. Kenan Yalta MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmet Yilmaz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Okan Onur Turgut MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Taner Erselcan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mehmet Birhan Yilmaz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Filiz Karadas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Can Yontar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Izzet Tandogan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yalta, K., Yilmaz, A., Turgut, O.O. et al. Evaluation of tumor markers CA-125 and CEA in acute myocardial infarction. Adv Therapy 23, 1052–1059 (2006). https://doi.org/10.1007/BF02850225

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02850225

Keywords

Search

Navigation